AR121666A1 - DERIVADOS DE NAFTIRIDINA Y PIRIDO[3,4-C]PIRIDAZINA COMO MODULADORES DEL RECEPTOR GABAA a5 - Google Patents
DERIVADOS DE NAFTIRIDINA Y PIRIDO[3,4-C]PIRIDAZINA COMO MODULADORES DEL RECEPTOR GABAA a5Info
- Publication number
- AR121666A1 AR121666A1 ARP210100754A ARP210100754A AR121666A1 AR 121666 A1 AR121666 A1 AR 121666A1 AR P210100754 A ARP210100754 A AR P210100754A AR P210100754 A ARP210100754 A AR P210100754A AR 121666 A1 AR121666 A1 AR 121666A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- formula
- haloalkyl
- cycloalkyl
- Prior art date
Links
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 title abstract 2
- DVXYZLCJSYRIPC-UHFFFAOYSA-N pyrido[3,4-c]pyridazine Chemical class C1=NN=C2C=NC=CC2=C1 DVXYZLCJSYRIPC-UHFFFAOYSA-N 0.000 title abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 12
- 150000001875 compounds Chemical class 0.000 abstract 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- -1 C3-cycloalkyl −7 Chemical group 0.000 abstract 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 102000027484 GABAA receptors Human genes 0.000 abstract 1
- 108091008681 GABAA receptors Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2000113 | 2020-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR121666A1 true AR121666A1 (es) | 2022-06-29 |
Family
ID=89666363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100754A AR121666A1 (es) | 2020-03-26 | 2021-03-26 | DERIVADOS DE NAFTIRIDINA Y PIRIDO[3,4-C]PIRIDAZINA COMO MODULADORES DEL RECEPTOR GABAA a5 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20240067637A1 (enExample) |
| EP (1) | EP4126859A1 (enExample) |
| JP (1) | JP7805946B2 (enExample) |
| KR (1) | KR20220160061A (enExample) |
| CN (1) | CN115348962A (enExample) |
| AR (1) | AR121666A1 (enExample) |
| AU (1) | AU2021244926A1 (enExample) |
| BR (1) | BR112022019128A2 (enExample) |
| CA (1) | CA3171441A1 (enExample) |
| CL (1) | CL2022002568A1 (enExample) |
| CO (1) | CO2022014877A2 (enExample) |
| CU (1) | CU24714B1 (enExample) |
| EC (1) | ECSP22082367A (enExample) |
| GE (2) | GEAP202416066A (enExample) |
| IL (1) | IL296716A (enExample) |
| JO (1) | JOP20220219A1 (enExample) |
| MX (1) | MX2022011933A (enExample) |
| PE (1) | PE20221836A1 (enExample) |
| PH (1) | PH12022552340A1 (enExample) |
| TW (1) | TWI901650B (enExample) |
| WO (1) | WO2021191838A1 (enExample) |
| ZA (1) | ZA202211414B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU231691B1 (hu) * | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| BRPI0617306A2 (pt) * | 2005-10-11 | 2011-07-19 | Hoffmann La Roche | derivados de isoxazol |
| BRPI0618383A2 (pt) * | 2005-11-09 | 2011-08-30 | Hoffmann La Roche | derivados de 3-aril-isoxazol-4-carbonil-benzofurano |
| HU230518B1 (hu) | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
| HUP0600808A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| AU2012225805B2 (en) * | 2011-03-04 | 2017-03-02 | Lexicon Pharmaceuticals, Inc. | MST1 kinase inhibitors and methods of their use |
| DK2937349T3 (en) | 2011-03-23 | 2017-02-20 | Amgen Inc | CONDENSED TRICYCLIC DUAL INHIBITORS OF CDK 4/6 AND FLT3 |
| CA2876778A1 (en) * | 2012-06-26 | 2014-01-03 | Saniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| KR20150033679A (ko) | 2012-06-26 | 2015-04-01 | 사니오나 에이피에스 | 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 |
| WO2014001278A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| CN102924452B (zh) * | 2012-11-16 | 2015-01-21 | 苏州施亚生物科技有限公司 | 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法 |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| CN112409363B (zh) | 2013-12-20 | 2023-11-14 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法 |
| US9296747B1 (en) * | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
| KR20180030545A (ko) * | 2015-06-22 | 2018-03-23 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 바이사이클릭 헤테로사이클릭 아미드 유도체 |
| JP2018525429A (ja) | 2015-08-28 | 2018-09-06 | アッヴィ・インコーポレイテッド | Ｓ１ｐ調節剤としての縮合複素環化合物 |
| PT3439665T (pt) | 2016-03-18 | 2022-09-27 | Uwm Res Foundation Inc | Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5 |
| UA125524C2 (uk) | 2016-12-08 | 2022-04-13 | Ф. Хоффманн-Ля Рош Аг | Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5 |
| WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| ES2902365T3 (es) | 2017-11-27 | 2022-03-28 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituidos como inhibidores de PDE1 |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| AU2019286312B2 (en) | 2018-06-13 | 2023-08-17 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as GABA A alpha5 PAM |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
| BR102019014802A2 (pt) | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
-
2021
- 2021-03-11 TW TW110108696A patent/TWI901650B/zh active
- 2021-03-25 GE GEAP202416066A patent/GEAP202416066A/en unknown
- 2021-03-25 MX MX2022011933A patent/MX2022011933A/es unknown
- 2021-03-25 KR KR1020227037372A patent/KR20220160061A/ko active Pending
- 2021-03-25 BR BR112022019128A patent/BR112022019128A2/pt unknown
- 2021-03-25 PE PE2022002114A patent/PE20221836A1/es unknown
- 2021-03-25 CU CU2022000058A patent/CU24714B1/es unknown
- 2021-03-25 GE GEAP202116066A patent/GEP20257761B/en unknown
- 2021-03-25 CA CA3171441A patent/CA3171441A1/en active Pending
- 2021-03-25 WO PCT/IB2021/052486 patent/WO2021191838A1/en not_active Ceased
- 2021-03-25 JP JP2022557102A patent/JP7805946B2/ja active Active
- 2021-03-25 IL IL296716A patent/IL296716A/en unknown
- 2021-03-25 EP EP21715334.5A patent/EP4126859A1/en active Pending
- 2021-03-25 AU AU2021244926A patent/AU2021244926A1/en active Pending
- 2021-03-25 CN CN202180023958.0A patent/CN115348962A/zh active Pending
- 2021-03-25 PH PH1/2022/552340A patent/PH12022552340A1/en unknown
- 2021-03-25 US US17/907,174 patent/US20240067637A1/en active Pending
- 2021-03-26 AR ARP210100754A patent/AR121666A1/es unknown
-
2022
- 2022-09-13 JO JOP/2022/0219A patent/JOP20220219A1/ar unknown
- 2022-09-22 CL CL2022002568A patent/CL2022002568A1/es unknown
- 2022-10-18 ZA ZA2022/11414A patent/ZA202211414B/en unknown
- 2022-10-19 CO CONC2022/0014877A patent/CO2022014877A2/es unknown
- 2022-10-22 EC ECSENADI202282367A patent/ECSP22082367A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022019128A2 (pt) | 2022-11-08 |
| TW202202495A (zh) | 2022-01-16 |
| PH12022552340A1 (en) | 2023-11-29 |
| PE20221836A1 (es) | 2022-11-29 |
| US20240067637A1 (en) | 2024-02-29 |
| JOP20220219A1 (ar) | 2022-09-13 |
| CA3171441A1 (en) | 2021-09-30 |
| GEP20257761B (en) | 2025-04-10 |
| ZA202211414B (en) | 2023-06-28 |
| JP7805946B2 (ja) | 2026-01-26 |
| GEAP202416066A (en) | 2024-12-10 |
| KR20220160061A (ko) | 2022-12-05 |
| AU2021244926A1 (en) | 2022-11-03 |
| CU20220058A7 (es) | 2023-05-11 |
| TWI901650B (zh) | 2025-10-21 |
| EP4126859A1 (en) | 2023-02-08 |
| CO2022014877A2 (es) | 2022-10-31 |
| IL296716A (en) | 2022-11-01 |
| CN115348962A (zh) | 2022-11-15 |
| JP2023520647A (ja) | 2023-05-18 |
| ECSP22082367A (es) | 2022-11-30 |
| CU24714B1 (es) | 2024-07-10 |
| CL2022002568A1 (es) | 2023-03-24 |
| WO2021191838A1 (en) | 2021-09-30 |
| MX2022011933A (es) | 2022-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR080878A1 (es) | Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos. | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR107928A1 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR088258A1 (es) | Inhibidores de la pde10 de azetidina 1,3-sustituida | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR111176A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos | |
| PE20201280A1 (es) | Amidas de imidazopiridina sustituidas y su uso | |
| AR060212A1 (es) | Compuestos de imidazo (1,2-b) piridacinas, procesos para su preparacion y de sus intermedios; usos de dichos compuestos; y composicion farmaceutica que los comprende | |
| AR115015A1 (es) | Derivados de azaespiro piperazina | |
| AR121296A1 (es) | Moduladores de monoacilglicerol lipasa | |
| MX2021008426A (es) | Nuevos derivados de sulfonilurea sustituida. | |
| AR121676A1 (es) | DERIVADOS DE BENZODIAZEPINAS COMO PAM DE GABAA g1 | |
| AR119790A1 (es) | Compuestos de isoxazolina y su uso como agentes para el control de plagas | |
| HRP20090565T1 (hr) | Novi triciklički derivati, postupak njihove priprave i farmaceutski pripravci koji ih sadrže | |
| AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
| AR118641A1 (es) | Compuestos, composiciones y métodos | |
| AR128494A1 (es) | Compuestos heterocíclicos, composiciones de los mismos y métodos de tratamiento con los mismos | |
| AR111826A1 (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| AR122143A1 (es) | Compuestos heterocíclicos |